Executive Wealth Management LLC acquired a new position in shares of Sanofi SA (NYSE:SNY) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 775 shares of the company’s stock, valued at approximately $34,000.
Several other institutional investors also recently made changes to their positions in SNY. Essex Savings Bank bought a new stake in shares of Sanofi in the fourth quarter valued at about $30,000. Claybrook Capital LLC bought a new stake in Sanofi during the fourth quarter worth about $31,000. Berman Capital Advisors LLC bought a new stake in Sanofi during the fourth quarter worth about $44,000. Lavaca Capital LLC bought a new stake in Sanofi during the fourth quarter worth about $51,000. Finally, Focused Wealth Management Inc raised its holdings in Sanofi by 33.2% during the fourth quarter. Focused Wealth Management Inc now owns 1,204 shares of the company’s stock worth $52,000 after acquiring an additional 300 shares in the last quarter. 7.04% of the stock is owned by institutional investors and hedge funds.
Shares of Sanofi stock traded up $0.22 on Friday, hitting $41.31. The stock had a trading volume of 1,575,659 shares, compared to its average volume of 997,073. Sanofi SA has a twelve month low of $37.43 and a twelve month high of $45.62. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $103.61 billion, a price-to-earnings ratio of 13.20, a PEG ratio of 2.41 and a beta of 0.67.
The business also recently declared an annual dividend, which will be paid on Friday, May 31st. Investors of record on Wednesday, May 8th will be paid a $1.7395 dividend. This represents a dividend yield of 4.2%. The ex-dividend date of this dividend is Tuesday, May 7th. Sanofi’s dividend payout ratio (DPR) is currently 38.34%.
In related news, major shareholder Sanofi sold 131,115 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.00% of the company’s stock.
Several analysts recently issued reports on SNY shares. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $47.00 target price on the stock in a report on Friday, January 18th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Monday, January 14th. TheStreet downgraded Sanofi from a “b” rating to a “c+” rating in a research report on Thursday, February 7th. Finally, HC Wainwright reissued a “buy” rating on shares of Sanofi in a research report on Thursday, February 28th. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $51.00.
ILLEGAL ACTIVITY NOTICE: This story was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.baseballdailydigest.com/news/2019/04/21/executive-wealth-management-llc-takes-34000-position-in-sanofi-sa-sny.html.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.